Apexign Inc (APGN)

Best of luck to all on the new ticker. Lets make money $$$$$

No brainer here to make alot of money! Loaded

APGN............................https://stockcharts.com/h-sc/ui?s=APGN&p=W&b=5&g=0&id=p86431144783

This should be trading higher with the acquisition

Nice got some $$$

Pyxis Oncology to Acquire Apexigen

Nice accumulation today with 4X the average 10 day volume. Nice increase in PPS for 44% something tells me that we are close to some great news. $APGN

Earnings are due today after the bell,someone knows something.

Insiders last bought in oct 22, no sells. Could this low floater be on the verge of a huge upside reversal. Patience is wealth

THE TREND IS YOUR FRIEND
LIKE down
The Illuminati and One World Government
From Genesis to the Tower of Babel, to the
Egyptian Pharaohs, to Goat God's, to the World Bank, and the
FreeMasons, Secret Societies, Rosicrucians,
Rothschild bloodline, sexual perversions,
Marxism, Communism, Illuminati, Evil 666 -

Whats up with this? Time to buy coming soooonnnnnn…… $$$$$

APGN...........................https://stockcharts.com/h-sc/ui?s=APGN&p=W&b=5&g=0&id=p86431144783

Pump and dump... they say in the 10Q that they have a deficit of 170 million and may seeek additional funds... They'll do a share offering.

Oversold! Squeeze time coming

Apexigen Inc. (APGN)
Roth Capital: Buy, $15 Target

https://pennystocks.com/featured/2023/01/25/4-penny-stocks-to-buy-according-to-analysts-targets-over-600/

Finally, Apexigen has pulled an about-face since the start of the new year. The company hit fresh, 52-week lows on the first day of trading for 2023 but so far has bounced back more than 100%. If analysts are to be believed, they expect much more, which we’ll discuss later in this section.

Apexigen develops antibody-based therapeutics for cancer treatment and recently posted new Phase 2 data. This data evaluated its sotigalimab in treating tumors in patients with esophageal/gastro-esophageal junction (E/GEJ) cancer and a separate study in rectal cancer tumors. The data was recently presented at the ASCO Gastrointestinal Cancers Symposium earlier this month.


Recent news regarding a $2.8 million financing deal doesn’t seem to have impacted the market. The funding round is expected to close by the end of this month, with proceeds going toward the ongoing Phase 2 study of sotigalimab.

What is the APGN stock forecast? Roth Capital recently reinstated its coverage of the company. The firm gave a Buy rating and price target of $15. APGN stock closed at $1.99 on Tuesday, which puts Roth Capitals forecast 654% higher.

Boom boom boom

Shorts better start loading warrants as a hedge,or risk getting more burned if it becomes the biggest runner of the day.

Institutional ownership increased from 25% to %29 in just 3 days, big news will send this to the moon, and we all know biotech's run hard when they do. Hang tight and you'll bank hard.

Best retailer that I love!

APGN: OLD "news" from 1-4-23 --- re-hashed to look EPIC for the Monday MARKETS!! PURE suckers' bait for today, Bro!! Did YOU jump-on-it right out of the starting gate????? I, too, almost grabbed some early today, but knew better. GOOD LUCK!!!

APGN: I had to back-off, Emperor EZ!! Was OLD news from 1-4-23; YES, an easy FLIP, for sure. Did you grab some??? CONGRATS, as likely you DID!!!

$APGN: Gettting and $8 PT from EF-HUTTON

APEXIGEN (APGN) STOCK JUMPED 126.8% ON POSITIVE STOCK RATING

SIMON MUGO

The Apexigen Inc (NASDQ: APGN) stock jumped 126.8% after EF Hutton Acquisition Co. initiated coverage of the stock with an $8.00 price target and a buy rating. The rating was issued on Wednesday, January 4, 2022, reigniting investor interest in the company.


The last significant announcement from the company was the release of its Q3 earnings results on November 15, 2022, where its earnings per share rose to $0.41, representing a slight improvement to last year’s $0.40 figure.

GO $APGN